Astrazeneca Share News (AZN)

AstraZeneca, Shire shares drop as U.S. tightens tax rules

LONDON, Sept 23 (Reuters) - Shares in drugmakers AstraZeneca and Shire both fell more than 5 percent on Tuesday after the U.S. Treasury took steps to curb "inversion" deals that allow companies to escape high U.S. taxes by reincorporating abroad. The move appears to jeopardise an agreed de

BUZZ-Weaker GBP offers a silver lining for UK MNCs

** When the dust settles following tonight's Scottish referendum, any sustained sterling weakness that arises will offer some UK bluechips something to cheer about. ** Impact of a stronger pound has been a key theme for last 2 quarterly earnings seasons and has hit revisions and EPS forecas

French cancer immunotherapy specialist OSE Pharma prepares IPO

* Seeking funding for Texopi late-stage trials * Aims to launch IPO by year-end PARIS, Sept 18 (Reuters) - French cancer immunotherapy specialist OSE Pharma has registered with market regulator AMF for an initial public offering (IPO) aimed at financing late-stage trials of its Texopi

UPDATE 1-Merck KGaA seeks partner for immuno-oncology drug by year-end

* Competitive process to find partner for anti-PD-L1 drug * Experimental drug in hot new area for cancer research * Merck plans increased investment in biosimilar drugs * Pharma head Oschmann appointed deputy CEO (Adds details on drug, wraps in management changes) FRANKF

BUZZ-Nektar Therapeutics: FDA approves constipation drug

** Biotechnology company's shares up 3 pct at $13.94 ** U.S. FDA approves oral therapy to treat opioid-induced constipation, co-developed with AstraZeneca Plc ** The drug will be sold under the trade name Movantik, and be launched in the first half of 2015, the companies said **

AstraZeneca Says US FDA Approves Opioid-Induced Constipation Treatment

CORRECTED-FDA approves AstraZeneca, Nektar constipation drug

(Corrects spelling of "Movantik" throughout) By Natalie Grover Sept 16 (Reuters) - The U.S. Food and Drug Administration approved an oral therapy to treat opioid-induced constipation developed by Nektar Therapeutics and AstraZeneca Plc . The decision opens the door for peripher

FDA approves AstraZeneca, Nektar constipation drug

By Natalie Grover Sept 16 (Reuters) - The U.S. Food and Drug Administration approved an oral therapy to treat opioid-induced constipation developed by Nektar Therapeutics and AstraZeneca Plc . The decision opens the door for peripherally acting mu opioid receptor antagonists, which h

UK MIDDAY BRIEFING: St James's Place Shares Fall As Ex-Partner Fined

TOP NEWS: UK House Prices Continue To Rise As Inflation Slows

Astrazeneca and Eli Lilly to develop Alzheimer's drug

Astrazeneca has agreed to jointly develop and commercialise AZD3293, a drug currently being tested as a potential treatment for Alzheimer's disease, with Eli Lilly. Lilly will pay Astra up to $500m in development and regulatory milestone payments, the first of which it expects to receive in the firs

UK MORNING BRIEFING: ASOS Down On Outlook, Pearson Up On Upgrade

UPDATE 1-AstraZeneca gets up to $500 mln from Lilly for Alzheimer's drug

* Lilly to partner on AstraZeneca's BACE inhibitor drug * Astra expects first $50 mln payment in first half 2015 * Full payout of up to $500 mln dependent on drug's success * AZD3293 seen high-risk but potential $5 bln-a-year seller (Adds further details on drug, sales forecas

AstraZeneca To Collaborate With Lilly On Alzheimer's Drug Development

AstraZeneca to partner with Eli Lilly on Alzheimer's drug

LONDON, Sept 16 (Reuters) - AstraZeneca has struck a partnership deal worth up to $500 million with Eli Lilly for the British group's experimental Alzheimer's drug, which is set to enter late-stage Phase III development. AstraZeneca said in May that it was looking to find a partner for it